Fumiharu Ohka

TL;DR: In this article, the authors delineate the entire picture of genetic alterations and affected pathways in these glioma types, with sensitive detection of driver genes Grade II and III gliomas comprise three distinct subtypes characterized by discrete sets of mutations and distinct clinical behaviors, suggesting that there is functional interplay between the mutations that drive clonal selection.

TL;DR: Results indicate that epigenetic regulation by PRC2 is a key mediator of tumor cell plasticity, which is required for the adaptation of glioblastoma cells to their microenvironment, andPRC2-targeted therapy may reduce tumor cell Plasticity and tumor heterogeneity, offering a new paradigm for glioma treatment.

TL;DR: The authors in this paper showed that TET1 methylation may contribute to the establishment of a unique pathway in respect to CIMP-mediated tumorigenesis, which may be incidental to hMLH 1 methylation.

TL;DR: OBP-801 may be a potent AR-targeting therapeutic reagent in AR-positive prostate cancer regardless of androgen dependency, and epigenetic upregulation of miR-320a resulted in tumor cell growth suppression of prostate cancers.

TL;DR: A LATS2 knockout cell line is constructed using TAL-effector nuclease to reveal a novel signal upstream of PRC2, and provide insight into the crucial role of LATS1 in coordinating the epigenome through regulation of PRc2.